Lung Kee Bermuda Holdings Ltd (0255) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Lung Kee Bermuda Holdings Ltd HK$3.25, price HK$1.36, upside +139.0%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Lung Kee Bermuda Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range HK$0.8640 – HK$2.69 · fair‑value band HK$2.66 – HK$4.00 · the HK$1.36 price screens below the HK$3.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Lung Kee Bermuda Holdings in your weekly email
Every Wednesday you see whether Lung Kee Bermuda Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Lung Kee Group Holdings Limited, an investment holding company, manufactures and markets mould bases and related products in the People's Republic of China and internationally. It also engages in property investment and corporate management activities.
Show more
Lung Kee Group Holdings Limited, an investment holding company, manufactures and markets mould bases and related products in the People's Republic of China and internationally. It also engages in property investment and corporate management activities. The company was formerly known as Lung Kee (Bermuda) Holdings Limited and changed its name to Lung Kee Group Holdings Limited in June 2024. The company was founded in 1975 and is headquartered in Sha Tin, Hong Kong. Lung Kee Group Holdings Limited operates as a subsidiary of Pan Island Investments Limited.
Stock analysis
Lung Kee Bermuda Holdings Ltd (0255) currently trades at HK$1.36, while our model-based Fair Value estimate is HK$3.25, implying the stock looks roughly 58.2% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of HK$3.09 per share, and 13 of the 13 models we run sit above the HK$1.36 price.
Bear case: the Asset-Based group reads lowest at HK$1.64, and 0 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$2.66 (bear) to HK$4.00 (bull), the price of HK$1.36 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Industrials sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Lung Kee Bermuda Holdings Ltd reported revenue of HK$1.3B in FY2025 versus HK$2.3B in FY2021, a compound −12.7%/yr. Reported net income was −HK$22.6M in FY2025.
Key figures
Market cap HK$859M (≈ $110M) · P/S ratio 0.68 · EPS (TTM) HK$−0.0100 · Dividend yield 14.7% · Net margin −1.7% · Return on equity −1.4% · Return on assets (EBIT) 0.1% · Operating margin −6.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −35% fair-value upside, at 139%, 0255 screens cheaper than that median.
Fair Value models
Bear HK$2.66Fair Value HK$3.25Bull HK$4.00
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.23/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.6%
Start year 2020 (pandemic). Over 10 years: −5.3% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.2% (2020) → −3.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−23.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about −24.8% a year for the price.
Compare Lung Kee Bermuda Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Metal Fabrication · 263 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Top 25%
Fair Value upside+137% · Top 25%
Profitability
Return on assets−1% · Bottom 25%
Net margin (TTM)−2% · Bottom 25%
Operating margin (TTM)−6% · Bottom 25%
Growth and dividend
Revenue growth−18% · Bottom 25%
Dividend yield (TTM)14.7% · Top 25%
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Metal Fabrication median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Lung Kee Bermuda Holdings Ltd (0255) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$3.25 versus a price of HK$1.36, about +139% upside (undervalued).
What is the fair value of 0255?
Our model-based fair value for Lung Kee Bermuda Holdings Ltd is HK$3.25 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$1.36.
What is the quality score of 0255?
Lung Kee Bermuda Holdings Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lung Kee Bermuda Holdings Ltd (0255)?
Our model-based price target is the fair value of HK$3.25 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario HK$2.66, optimistic scenario HK$4.00. It is a calculation from audited fundamentals, not an analyst target.
What is the Lung Kee Bermuda Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$3.25, about +139% upside versus a price of HK$1.36 (undervalued). Cautious scenario HK$2.66, optimistic scenario HK$4.00. The calculation is refreshed regularly with new filings.
What is the revenue of Lung Kee Bermuda Holdings Ltd (0255)?
Lung Kee Bermuda Holdings Ltd reported trailing-twelve-month revenue of about HK$1.3B (latest available figure, as of Sep 24, 2026).
Does Lung Kee Bermuda Holdings Ltd pay a dividend?
Lung Kee Bermuda Holdings Ltd currently shows a dividend yield of about 14.71% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Lung Kee Bermuda Holdings Ltd (0255)?
For today's price to be fair in a discounted-cash-flow model, Lung Kee Bermuda Holdings Ltd would have to grow free cash flow by -23.2 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -8.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0255 use?
Our models discount Lung Kee Bermuda Holdings Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.25, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Lung Kee Bermuda Holdings Ltd that is -23.2 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Lung Kee Bermuda Holdings Ltd (0255) delivered so far?
Over the past 5 years revenue at Lung Kee Bermuda Holdings Ltd grew -8.6 % a year. The price currently implies -23.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Lung Kee Bermuda Holdings Ltd (0255) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into Lung Kee Bermuda Holdings Ltd (-23.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Lung Kee Bermuda Holdings Ltd (0255)?
The free-cash-flow yield on the price is 20.16 %: that much free cash flow Lung Kee Bermuda Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Lung Kee Bermuda Holdings Ltd (0255)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lung Kee Bermuda Holdings Ltd it is HK$3.25 per share (as of Sep 24, 2026), against a price of HK$1.36. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Lung Kee Bermuda Holdings Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0255 trades below its calculated fair value: price HK$1.36, fair value HK$3.25, a gap of about +139% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0255?
No. The price is what the market pays today (HK$1.36); the fair value is what the company's own numbers justify (HK$3.25). For Lung Kee Bermuda Holdings Ltd the two are HK$1.89 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lung Kee Bermuda Holdings Ltd worth?
The market values Lung Kee Bermuda Holdings Ltd at about HK$859M (market capitalisation, as of Sep 24, 2026). Per share that is HK$1.36; our models calculate a fair value of HK$3.25 per share.
What do the bullish and bearish scenarios say about 0255?
Our models span a range for Lung Kee Bermuda Holdings Ltd: cautious scenario HK$2.66, base HK$3.25, optimistic HK$4.00 per share (as of Sep 24, 2026, price HK$1.36). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lung Kee Bermuda Holdings Ltd (0255)?
Balance-sheet figures for Lung Kee Bermuda Holdings Ltd (as of Sep 24, 2026): return on equity −1.4%, debt of 0.14 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 0255 from its 52-week high?
Lung Kee Bermuda Holdings Ltd trades at HK$1.36, about 25% below its 52-week high of HK$1.82 and 10% above the low of HK$1.24 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$3.25 is for.
Which stocks are comparable to Lung Kee Bermuda Holdings Ltd?
From the same area (Industrials) we also value Carpenter Technology Corporation, ATI Inc, Mueller Industries, Inc, Aurubis AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lung Kee Bermuda Holdings Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price HK$1.36, calculated fair value HK$3.25 (+139%), Quality Score 60/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0255 calculated?
We run Lung Kee Bermuda Holdings Ltd through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$3.25, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Lung Kee Bermuda Holdings Ltd currently trades 139 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lung Kee Bermuda Holdings Ltd (0255)?
The closing price on Sep 24, 2026 was HK$1.36. Our model-based fair value is HK$3.25, about +139% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lung Kee Bermuda Holdings Ltd right now?
The price is below even our cautious bear case (HK$2.66). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Lung Kee Bermuda Holdings Ltd
How large is the market capitalisation of Lung Kee Bermuda Holdings Ltd (0255)?
The market capitalisation of Lung Kee Bermuda Holdings Ltd is HK$859M (≈ $110M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lung Kee Bermuda Holdings Ltd (0255)?
The price-to-sales ratio of Lung Kee Bermuda Holdings Ltd is 0.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lung Kee Bermuda Holdings Ltd (0255)?
Earnings per share at Lung Kee Bermuda Holdings Ltd are HK$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Lung Kee Bermuda Holdings Ltd (0255)?
The dividend yield of Lung Kee Bermuda Holdings Ltd is 14.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Lung Kee Bermuda Holdings Ltd (0255)?
The net margin of Lung Kee Bermuda Holdings Ltd is −1.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lung Kee Bermuda Holdings Ltd (0255)?
The return on equity (ROE) of Lung Kee Bermuda Holdings Ltd is −1.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lung Kee Bermuda Holdings Ltd (0255)?
On an EBIT basis the return on assets of Lung Kee Bermuda Holdings Ltd is 0.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lung Kee Bermuda Holdings Ltd (0255)?
The operating margin of Lung Kee Bermuda Holdings Ltd is −6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lung Kee Bermuda Holdings Ltd (0255)?
Revenue at Lung Kee Bermuda Holdings Ltd is growing −17.8% versus a year earlier (3y avg −6.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lung Kee Bermuda Holdings Ltd (0255)?
Earnings per share at Lung Kee Bermuda Holdings Ltd are growing −62.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Lung Kee Bermuda Holdings Ltd (0255) hold?
Lung Kee Bermuda Holdings Ltd holds more cash than debt, HK$584M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Lung Kee Bermuda Holdings Ltd in the live analysis
One click puts Lung Kee Bermuda Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
